S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
NASDAQ:TWST

Twist Bioscience Stock Forecast, Price & News

$112.11
-8.96 (-7.40 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$111.78
$120.80
50-Day Range
$95.64
$124.12
52-Week Range
$66.12
$214.07
Volume375,947 shs
Average Volume710,085 shs
Market Capitalization$5.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.7
30 days | 90 days | 365 days | Advanced Chart
Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.


Twist Bioscience logo

About Twist Bioscience

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. The company was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

836th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

127th out of 193 stocks

Analyst Opinion: 1.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

Is Twist Bioscience a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Twist Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TWST, but not buy additional shares or sell existing shares.
View analyst ratings for Twist Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Twist Bioscience?

Wall Street analysts have given Twist Bioscience a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Twist Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Monday, November 22nd 2021.
View our earnings forecast for Twist Bioscience
.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings data on Thursday, August, 5th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.07. The business earned $35.02 million during the quarter, compared to analyst estimates of $32.43 million. Twist Bioscience had a negative net margin of 106.59% and a negative trailing twelve-month return on equity of 24.59%. The firm's quarterly revenue was up 65.1% on a year-over-year basis. During the same period last year, the company posted ($0.67) earnings per share.
View Twist Bioscience's earnings history
.

How has Twist Bioscience's stock price been impacted by Coronavirus?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TWST stock has increased by 297.6% and is now trading at $112.11.
View which stocks have been most impacted by COVID-19
.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience updated its FY 2021 earnings guidance on Friday, September, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $129 million-$132 million, compared to the consensus revenue estimate of $127.12 million.

What price target have analysts set for TWST?

6 brokers have issued 1-year target prices for Twist Bioscience's shares. Their forecasts range from $100.00 to $150.00. On average, they anticipate Twist Bioscience's share price to reach $118.00 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price.
View analysts' price targets for Twist Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Emily Marine Leproust, Chairman, President & Chief Executive Officer
  • Patrick Weiss, Chief Operating Officer (LinkedIn Profile)
  • James M. Thorburn, Chief Financial Officer
  • Siyuan Chen, Chief Technology Officer
  • Aaron K. Sato, Chief Scientific Officer

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience CEO Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among Twist Bioscience's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.34%), Vanguard Group Inc. (8.48%), BlackRock Inc. (7.88%), Sumitomo Mitsui Trust Holdings Inc. (5.17%), Nikko Asset Management Americas Inc. (5.16%) and Invesco Ltd. (3.91%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends for Twist Bioscience
.

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Ikarian Capital LLC, Bank of New York Mellon Corp, FMR LLC, Jennison Associates LLC, Invesco Ltd., and Allianz Asset Management GmbH. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, and William Banyai.
View insider buying and selling activity for Twist Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Vanguard Group Inc., Marshall Wace LLP, Goldman Sachs Group Inc., Price T Rowe Associates Inc. MD, Macquarie Group Ltd., and State Street Corp.
View insider buying and selling activity for Twist Bioscience
or or view top insider-buying stocks.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $112.11.

How much money does Twist Bioscience make?

Twist Bioscience has a market capitalization of $5.53 billion and generates $90.10 million in revenue each year. The company earns $-139,930,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Twist Bioscience have?

Twist Bioscience employs 525 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

Where are Twist Bioscience's headquarters?

Twist Bioscience is headquartered at 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (800) 719-0671 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.